We describe the color Doppler sonographic features of uterine arteriovenous malformations in two cases. In both cases color Doppler imaging demonstrated hypervascularity throughout the arteriovenous malformation. The dominance of pale shades during both systole and diastole represented low-impedance, high-velocity flow within the lesion and a colored mosaic pattern representing turbulent flow was noted. Spectral analysis of the vessels within the lesion confirmed high-velocity flow during both systole and diastole, and a low resistance index. The spectral waveform trace also showed spectral broadening consistent with turbulence and the spectral envelope was irregular. These findings indicated the presence of numerous arteriovenous shunts and marked turbulence within the arteriovenous malformation. Spectral analysis of the venous flow revealed high flow velocities and systolic velocity peaks similar to an arterial pattern. The uterine artery velocity waveforms were characterized by high flow velocity and a low resistance index. The diagnosis of uterine arteriovenous malformation was confirmed by histological examination in both cases. The findings of these two cases suggest that color Doppler sonography may play an important role in the diagnosis of uterine arteriovenous malformations.
The purpose of this study was to investigate whether second-trimester amniocentesis increases fetal loss rate. Two thousand sixty-eight women with singleton gestations who underwent mid-trimester amniocentesis at 15 to 22 weeks gestation and 2068 controls matched one-to-one for maternal age, parity, and the number of prior spontaneous abortions were studied prospectively in a case-control study design. The fetal loss rates and other adverse pregnancy outcomes were compared between the study and control groups using the Pearson chi2 test or Fisher exact test when appropriate. In the amniocentesis group, eight (0.4%) fetal losses occurred within 30 days of the procedure, and in the control group, six (0.3%) losses occurred within 30 days of the inclusion in the study; the difference was not statistically significant ( p = 0.59; OR, 1.34; 95% CI, 0.46 to 3.85). The total fetal loss rates including spontaneous abortions and intrauterine fetal deaths/stillbirths were 2.3 and 2% in the study and control groups, respectively, and the difference was not significant ( p = 0.59; OR, 1.12; 95% CI, 0.74 to 1.71). Amniotic fluid leakage occurred in only two (0.1%) of 2068 study patients. Transplacental needle passage was not associated with an increased risk of pregnancy loss compared with nontransplacental amniocentesis ( p = 0.92; OR, 0.96; 95% CI, 0.47 to 1.95). There was no statistically significant difference in fetal loss rate between women requiring two needle insertions to obtain amniotic fluid and those having only one insertion ( p = 1.00; OR, 0.75; 95% CI, 0.10 to 5.53). The rates of preterm deliveries, small for gestational age infants, preeclampsia/eclampsia, placental abruptions, and cesarean deliveries were also not significantly different between two groups (each p > 0.05). We conclude that second-trimester amniocentesis for prenatal diagnosis is a safe procedure that does not appear to increase fetal loss rate.
Four hundred and four coagulase-negative staphylococci were isolated from 4905 urine specimens obtained from 4192 inpatients and outpatients. The distribution of the strains was as follows: 193 Staphylococcus epidermidis (47.8%), 171 Staphylococcus saprophyticus (42.3%), 29 Staphylococcus haemolyticus (7.2%), 5 Staphylococcus warneri (1.2%), 3 Staphylococcus schleiferi (0.7%), 2 Staphylococcus hominis (0.5%) and 1 Staphylococcus simulans (0.2%). All three Staphylococcus schleiferi strains were isolated from inpatients: a 64-year-old female, a 68-year-old male and a 3-month-old male with colony counts of 468,000 cfu/ml, 324,000 cfu/ml and 764,000 cfu/ml respectively. These findings show that among coagulase-negative staphylococci, Staphylococcus schleiferi, a newly described species of coagulase-negative staphylococci not previously reported as a uropathogen, may also cause hospital acquired urinary tract infection.
Six months of estrogen therapy (ET) and combined estrogen-progestogen therapy (EPT) significantly lower fasting plasma homocysteine levels in healthy postmenopausal women with equal efficacy.
Objective: To find out whether there is considerable influence on second trimester serum concentrations owing to the rhesus status.Study design: This retrospective cohort study was performed at the Perinatology Unit of the GATA Haydarpasa Teaching Hospital. During the study interval, 2265 pregnancies met inclusion criteria. The blood samples were collected in 117 pregnancies with a maternal rhesusnegative blood group status. The control group consisted of 2148 pregnancies with a maternal rhesus-positive blood group status. Statistical analysis was performed by SPSS 11.0 statistical software.Results: Pregnancies with a maternal rhesus-negative blood group status were identified in 117 patients. The overall prevalence of pregnancies with a maternal rhesus-negative blood group status were 5.1% in our study. Only unconjugated estriol multiples of the median values were significantly decreased in rhesus-negative women (P<0.001). Alpha-fetoprotein and human chorionic gonadotrophin multiples of the median values did not differ significantly (P>0.05). Conclusion:We conclude that if second trimester screening test to be used in Rh negative pregnancies, either the corrected value should be referred or double test result should be considered ignoring the unconjugated estriol result. Another option is the first trimester Down syndrome screening test.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.